

Help Shape the Future of Anxiety Treatment
Researchers from the University of Canterbury and oVRcome are looking for people to participate in a clinical research study evaluating new approaches to treating OCD and PTSD.
Physiology-Personalised Virtual Reality Exposure Therapy for Anxiety Disorders
Info Sheet
If eligible, you'll receive clinician-guided treatment as part of the study while helping advance research into more accessible mental health care.
You may be eligible if you:
-
Are 18-64 years old
-
Live in or can travel to Christchurch
-
Experience symptoms of Obsessive-Compulsive Disorder (OCD) or Post-Traumatic Stress Disorder (PTSD)
-
Own a smartphone with internet access
-
Can read and understand English
-
Are willing to participate in a 6-week treatment programme and follow-up assessments
What does participation involve?
If you're eligible, you'll be randomly assigned to one of two treatment groups:
-
Clinician-guided routine care
-
A personalised virtual reality treatment programme supervised by a clinician
Depending on your group, participation may include clinic visits, home-based activities, and brief questionnaires throughout the study.
This study may not be suitable if you:
-
Are under 18 or over 64 years of age
-
Are currently receiving psychological treatment for OCD or PTSD (unless your treatment has been stable for at least 3 months)
-
Have severe depression or active suicidal thoughts
-
Have a seizure disorder
-
Do not have access to a smartphone or internet
Register Your Interest
Registering takes around 2 minutes.
After registering, a member of the research team will contact you to arrange a confidential screening to determine whether you're eligible to participate.
No obligation
Registering your interest does not commit you to taking part.
Your information is confidential
Your details will only be used by the research team for this study.
Randomised study
Eligible participants are randomly allocated to one of two treatment groups.
Please note: If you are registering please do not download oVRcome as you will be ineligible for the clinical trial.